Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Release Date: December 23, 2025

Expiration Date: December 23, 2026

Activity Overview

The neonatal Fc receptor (FcRn) rescues immunoglobulin G (IgG) from lysosomal degradation, prolonging IgG half-life. FcRn blockade accelerates degradation of pathogenic IgG autoantibodies, leading to rapid, reversible reductions in circulating AChR and MuSK antibodies without broad immune suppression. This educational program for neurologists provides a focused, clinically grounded update on the role of FcRN blockade in the management of generalized myasthenia gravis (gMG). Emphasis is placed on the pathophysiologic rationale for targeting FcRN and how this strategy translates into meaningful clinical benefit for patients.

The program features experienced neuromuscular specialists who integrate pivotal clinical trial data with real-world insights drawn from years of treating patients with gMG. Faculty review efficacy and safety outcomes from key studies of FcRN blockers, discuss patient selection and timing of therapy, and address practical considerations such as onset of action and durability of response. Participants will gain a clear understanding of where FcRN blockers fit within the evolving gMG treatment landscape and how to apply evidence-based strategies to optimize outcomes in appropriate patients.

Target Audience

This educational activity is directed toward neurologists, specialty NPs and PAs, and other HCPs involved in the management of gMG.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify the role of FcRN in the pathophysiology of generalized myasthenia gravis
• Assess emerging data for FcRN-targeted therapies for generalized myasthenia gravis in relation to treatment outcomes
• Incorporate novel agents into individualized multidisciplinary management plans for patients with generalized myasthenia gravis.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.